Elmunzer B Joseph, Singal Amit G, Sussman Jeremy B, Deshpande Amar R, Sussman Daniel A, Conte Marisa L, Dwamena Ben A, Rogers Mary A M, Schoenfeld Philip S, Inadomi John M, Saini Sameer D, Waljee Akbar K
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan, USA.
Department of Internal Medicine, Division of Digestive and Liver Diseases and the Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Gastrointest Endosc. 2015 Mar;81(3):700-709.e3. doi: 10.1016/j.gie.2014.10.033.
Comparative effectiveness data pertaining to competing colorectal cancer (CRC) screening tests do not exist but are necessary to guide clinical decision making and policy.
To perform a comparative synthesis of clinical outcomes studies evaluating the effects of competing tests on CRC-related mortality.
Traditional and network meta-analyses. Two reviewers identified studies evaluating the effect of guaiac-based fecal occult blood testing (gFOBT), flexible sigmoidoscopy (FS), or colonoscopy on CRC-related mortality.
gFOBT, FS, colonoscopy.
Traditional meta-analysis was performed to produce pooled estimates of the effect of each modality on CRC mortality. Bayesian network meta-analysis (NMA) was performed to indirectly compare the effectiveness of screening modalities. Multiple sensitivity analyses were performed.
Traditional meta-analysis revealed that, compared with no intervention, colonoscopy reduced CRC-related mortality by 57% (relative risk [RR] 0.43; 95% confidence interval [CI], 0.33-0.58), whereas FS reduced CRC-related mortality by 40% (RR 0.60; 95% CI, 0.45-0.78), and gFOBT reduced CRC-related mortality by 18% (RR 0.82; 95% CI, 0.76-0.88). NMA demonstrated nonsignificant trends favoring colonoscopy over FS (RR 0.71; 95% CI, 0.45-1.11) and FS over gFOBT (RR 0.74; 95% CI, 0.51-1.09) for reducing CRC-related deaths. NMA-based simulations, however, revealed that colonoscopy has a 94% probability of being the most effective test for reducing CRC mortality and a 99% probability of being most effective when the analysis is restricted to screening studies.
Randomized trials and observational studies were combined within the same analysis.
Clinical outcomes studies demonstrate that gFOBT, FS, and colonoscopy are all effective in reducing CRC-related mortality. Network meta-analysis suggests that colonoscopy is the most effective test.
目前尚无关于相互竞争的结直肠癌(CRC)筛查试验的比较有效性数据,但这些数据对于指导临床决策和政策制定是必要的。
对评估相互竞争的试验对CRC相关死亡率影响的临床结局研究进行比较性综合分析。
传统荟萃分析和网状荟萃分析。两名评审员确定了评估基于愈创木脂的粪便潜血试验(gFOBT)、乙状结肠镜检查(FS)或结肠镜检查对CRC相关死亡率影响的研究。
gFOBT、FS、结肠镜检查。
进行传统荟萃分析以得出每种检查方式对CRC死亡率影响的合并估计值。进行贝叶斯网状荟萃分析(NMA)以间接比较筛查方式的有效性。进行了多项敏感性分析。
传统荟萃分析显示,与未干预相比,结肠镜检查使CRC相关死亡率降低了57%(相对风险[RR]0.43;95%置信区间[CI],0.33 - 0.58),而FS使CRC相关死亡率降低了40%(RR 0.60;95% CI,0.45 - 0.78),gFOBT使CRC相关死亡率降低了18%(RR 0.82;95% CI,0.76 - 0.88)。NMA显示在降低CRC相关死亡方面,倾向于结肠镜检查优于FS(RR 0.71;95% CI,0.45 - 1.11)以及FS优于gFOBT(RR 0.74;95% CI, 0.51 - 1.09)的趋势不显著。然而,基于NMA的模拟显示,结肠镜检查有94%的概率是降低CRC死亡率最有效的检查,当分析仅限于筛查研究时,有99%的概率是最有效的。
在同一分析中合并了随机试验和观察性研究。
临床结局研究表明,gFOBT、FS和结肠镜检查在降低CRC相关死亡率方面均有效。网状荟萃分析表明结肠镜检查是最有效的检查。